Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04328740 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of Oral TP-1454
A Phase 1 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT04328740 is a Phase 1 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 31 participants.
The verdict
NCT04328740, a Phase 1 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
This study will evaluate the safety and tolerability of oral TP-1454 in patients with advanced metastatic or progressive solid tumors and anal cancer.
Interventions
- DRUG TP-1454 monotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2020-07-08 |
| Est. Completion | 2025-04-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04328740
The ClinicalTrials.gov registry entry for NCT04328740 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TP-1454 monotherapy is the first listed.
NCT04328740 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04328740 about?
NCT04328740 is a clinical study titled "Phase 1 Study of Oral TP-1454". This study will evaluate the safety and tolerability of oral TP-1454 in patients with advanced metastatic or progressive solid tumors and anal cancer.
What is the current status of trial NCT04328740?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2020-07-08. Estimated completion is 2025-04-25.
What interventions are being tested in trial NCT04328740?
The interventions under investigation include: TP-1454 monotherapy (DRUG).
Who is sponsoring clinical trial NCT04328740?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.